Total amount: € 0,00
HOW TO ORDER
A Journal on Internal Medicine
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236
Minerva Medica 2015 June;106(3):133-41
HDL-cholesterol is associated with systemic inflammation in cardiac syndrome X
Tenekecioglu E. 1, Yilmaz M. 1, Demir S. 2, Bekler A. 3, Ozluk O. A. 4, Aydin U. 4, Goncu T. 4, Yontar O. C. 1 ✉
1 Department of Cardiology, Bursa Yuksek Ihtisas Education and Research Hospital, Ankara Yolu, Yildirim/Bursa, Bursa, Turkey;
2 Department of Cardiology, Adana Public Hospital, Karatas Yolu, Adana, Turkey;
3 Canakkale Onsekiz Mart, University Medicine School, Canakkale, Turkey;
4 Bursa Yuksek Ihtisas Education and Research Hospital, Bursa, Turkey
AIM: Microvascular inflammation is associated with cardiac syndrome X (CSX). High-density lipoprotein cholesterol (HDL-C) reveals antiatherogenic features with stimulating endothelial NO production, inhibiting oxidative stress and vascular inflammation. We investigated relationship between HDL-C and inflammatory markers in CSX.
METHODS: Hundred patients with CSX and control group of 80 subjects were evaluated. Hematologic indices, lipid levels and C-reactive protein (CRP) levels were studied in patients underwent coronary angiography.
RESULTS: CRP levels were higher in CSX group than control group (4.59±3.82 mg/dL vs. 2.48±1.32 mg/dL, P<0.001). HDL-C was significantly lower in CSX group compared to control group (36.5±4.0 mg/dL vs. 47.5±12.7 mg/dL, P=0.008). White blood cell (WBC) count was higher in CSX group than in control group. Neutrophil-lymphocyte ratio (NLR) was found significantly increased in CSX group as compared to control group. On multivariate linear regression, lower HDL-C was found to be a significant predictor of higher NLR in patients with CSX independent from other clinical and biochemical variables.
CONCLUSION: Lower HDL-C is associated with systemic inflammation in CSX. In patients with typical angina and normal epicardial coronaries,HDL-C and inflammatory markers should be investigated; one of the goals of treatment should be raising HDL-C.